About
Atomic AI builds ATOM-1, an RNA foundation model and integrated wet-lab R&D platform for predicting RNA structure and function and designing RNA-targeted small molecules and RNA-based medicines. It is aimed at biopharma and other drug-development partners; its differentiator is combining atomic-level AI models with structural biology and in-house assays to pursue traditionally undruggable targets.
Market
Atomic AI competes in AI-enabled drug discovery and RNA therapeutics, positioning itself around atomic-precision prediction of RNA structure and function. Its differentiation is the combination of the ATOM-1 RNA foundation model, chemical-mapping data, structural biology, and an integrated in-house wet lab, whereas Deep Genomics and broader AI-drug-discovery platforms represent the closest identifiable alternatives.
Atomic AI appears to target biotechnology and biopharmaceutical companies pursuing RNA-centric medicines, particularly RNA-targeted small molecules and therapeutics for traditionally undruggable targets. Its likely buyers and partners are biopharma R&D, drug-discovery, and business-development teams seeking AI-enabled RNA design capabilities.
At a Glance
Problem
Atomic AI addresses a core bottleneck in drug discovery: RNA biology is structurally complex, and many potentially valuable RNA targets have historically been difficult or impossible to drug selectively. The resulting problem is a high-risk, expensive path from biological insight to medicines, particularly when conventional approaches cannot identify compounds with sufficient potency and selectivity. Its central use case is turning traditionally “undruggable” RNA targets into viable therapeutic opportunities.
Product / Service
Atomic AI combines machine learning with structural biology to develop RNA-centric medicines, including RNA-targeted small molecules and RNA-based therapeutics. Its ATOM-1 foundation model is designed to predict RNA structure and function with high precision, providing a computational foundation for selecting and designing compounds against difficult targets. The company’s initial focus is deliberately designed, highly selective and potent RNA-targeted small molecules, with the intended benefit of expanding the range of treatable disease mechanisms.
Atomic AI also offers a partnership model: it is actively seeking collaborations in which other companies use ATOM-1 to develop RNA-centric medicines aligned with their strategic priorities. This gives the company a way to combine its platform and scientific capabilities with partners’ therapeutic areas, development resources and commercialization reach.
Market
Atomic AI competes in the emerging AI-enabled drug discovery and RNA therapeutics market, specifically at the intersection of machine learning, structural biology and RNA-targeted medicines. The available research does not identify named direct competitors, so the most defensible comparison set is other biotech and platform companies applying AI and structural biology to difficult molecular targets and RNA-based drug development.
The company has raised $42 million and is actively seeking partnerships, indicating meaningful platform and financing traction. However, the available evidence does not disclose product revenue, approved medicines, clinical-stage assets or commercial milestones, so it should be treated as a development-stage biotech whose current market position is based primarily on its ATOM-1 platform, scientific team and partnership strategy rather than demonstrated commercial revenue.
Founders & Leadership
Funding History
8VC
Playground Global
Recent News
NewMarketPitch lists Atomic AI as an RNA drug-discovery startup and reports approximately $42 million in funding.
Tracxn’s company profile describes Atomic AI as a San Francisco Series A company operating an AI-based RNA drug-discovery platform, and reports that it has raised $42 million.
Notice’s profile describes Atomic AI as developing computational and experimental tools for modeling RNA structure and interactions, using machine learning and structural biology.
BiopharmaTrend highlights Atomic AI’s ATOM-1™ model component, which uses in-house chemical-mapping data to predict RNA structure. The article also reports approximately $42 million raised across seed and Series A rounds.
A video feature presents Atomic AI as a biotech company combining artificial intelligence and structural biology to develop RNA-targeted therapeutics.
Active Roles
1Business Model
Atomic AI operates a partnership-led biotech model: it seeks collaborations with other companies to apply its ATOM-1 foundation model and proprietary R&D platform to RNA-centric drug development. The available evidence does not disclose subscription pricing; commercial value is most likely generated through partnered drug-development programs, licensing, and eventual therapeutic commercialization.
Products
Tech Stack
Similar Companies
Competitors
Key Investors
Playground Global, 8VC, Greylock, Nat Friedman